Absence of Nephro-Protective Effect of Acetylcysteine in Patients with Chronic Renal Failure Investigated by Coronary Angiography;Absence d'Effet Néphroprotecteur de l'Acétylcystéine Chez les Patients Avec Insuffisance Rénale Chronique Explorés par Coronarographie

Archives des Maladies du Coeur et des Vaisseaux

Volumn 96, Issue 12, 2003, Pages 1157-1161

  El Mahmoud, R ^a   Le Feuvre, C ^a   Le Quan Sang, K H ^b   Helft, G ^a   Beygui, F ^a   Batisse, J P ^a   Metzger, J P ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CREATININE; IODINATED CONTRAST MEDIUM; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; SODIUM CHLORIDE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HYDRATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PROTECTION; RENAL PROTECTION;

ACETYLCYSTEINE; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; IOXAGLIC ACID; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; MALE; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 1542269221     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Tepel M, Van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184.
2. Diaz-Sandoval LJ, Kosowsky B, Losordo D. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002; 89: 356-58.
3. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002; 40: 1383-8.
4. Durham JD, Caputo C, Dokko J et al. A randomised controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002; 62: 2202-7.
5. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 402: 298-303.
6. Cockcroft DW, Gault MH. Prediction of creatine clearance from serum creatinine. Nephron 1976; 16: 31-41.
7. Gruberg L, Mintz GS, Mehran R et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000; 36: 1542-8.
8. Mc Cullough PA, Wolyn R, Rocher LL et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-75.
9. Ansari A, Kaupke C, Vaziri N et al. Cardiac pathology in patients with end-stage renal disease maintained on hemo dialysis. Int J Artif Organs 1993; 16: 31-6.
10. Le Feuvre C. Angioplasty and stenting in patients with renal disease. Heart 2000; 83: 7-8.
11. Soma VR, Cavusoglu E, Vidhun R et al. Contrast-associated nephropathy. Heart Dis 2002; 4: 372-9.
12. Scolari F, Tardanico R, Zani R et al. Cholesterol crystal embolism: a recognizable cause of renal disease. Am J Kidney Dis 2000; 36: 1089-109.
13. Mueller C, Buerkle G, Buettner HJ et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1 620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-36.
14. Barrett BJ, Parfrey PS, Morton BC. Safety and criteria for selective use of low-osmolality contrast for cardiac angiography. Med Care 1998; 36: 1189-97.
15. Manske CL, Sprafka JM, Strony JT et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615-20.
16. Wang A, Holcslaw T, Bashore TM et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. 2000; 58: 2239.
17. Solomon R, Werner C, Mann D et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-20.
18. Kini AA, Sharma SK. Managing the high-risk patient: experience with fenoldopam selective dopamine receptor antagonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention. Rev Cardiovasc Med 2001; 2 (Suppl. 1): S19-S25.
19. Madyoon H. Clinical experience with the use of fenoldopam for prevention radiocontrast nephropathy in high-risk patients. Rev Cardiovasc Med 2001; 2 (Suppl. 1): S26-S30.